| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H29ClN4O6 |
| Molecular Weight | 480.942 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC[C@H](O)CN1C(=O)C=NN(C1=O)C2=CC(C(=O)NCC3(O)CCCCCC3)=C(Cl)C=C2
InChI
InChIKey=FUCKCIVGBCBZNP-MRXNPFEDSA-N
InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1
| Molecular Formula | C22H29ClN4O6 |
| Molecular Weight | 480.942 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CE-224535 is a potent, highly selective, orally bioavailable, non-competitive antagonist of the human P2X7 receptor. Pre-clinical pharmacokinetic studies with CE-224535 indicate limited CNS penetration. In clinical trials, CE-224535 failed to demonstrate efficacy in a 2-week study of knee pain in osteoarthritis or a 12-week study in patients with rheumatoid arthritis. CE-224535 is safe and well tolerated after administration of up to 1600 mg as a single dose or 600 mg every 12 hours for 14 days in healthy subjects and 500 mg every 12 hours for 2 weeks in subjects with osteoarthritis of the knee and 12 weeks in rheumatoid arthritis patients with an inadequate response to methotrexate.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
